D-Index & Metrics Best Publications

Ronald A. Lubet

National Institutes of Health
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 75 Citations 20,050 387 World Ranking 14539 National Ranking 7485

Overview

What is he best known for?

The fields of study Ronald A. Lubet is best known for:

Cancer
Breast cancer
Estrogen

His work often combines Cancer and Cell growth studies. Borrowing concepts from Cancer, he weaves in ideas under Cell growth. His Pathological research extends to Internal medicine, which is thematically connected. His work on Internal medicine expands to the thematically related Pathological. He conducts interdisciplinary study in the fields of Estrogen receptor and Antiestrogen through his research. Ronald A. Lubet applies his multidisciplinary studies on Antiestrogen and Tamoxifen in his research. While working in this field, Ronald A. Lubet studies both Tamoxifen and Estrogen. He integrates several fields in his works, including Estrogen and Mammary gland. Mammary gland and Mammary tumor are two areas of study in which Ronald A. Lubet engages in interdisciplinary research.

His most cited work include:

A Chemically Induced Model for Squamous Cell Carcinoma of the Lung in Mice (106 citations)
Health disparities in breast cancer: biology meets socioeconomic status (95 citations)
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer (56 citations)

What are the main themes of his work throughout his whole career to date

His study brings together the fields of Progesterone receptor and Internal medicine. Ronald A. Lubet performs integrative Cancer and Hyperplasia research in his work. He merges many fields, such as Hyperplasia and Breast cancer, in his writings. He performs multidisciplinary study in the fields of Breast cancer and Progesterone receptor via his papers. In his papers, he integrates diverse fields, such as Cancer research and Carcinogenesis. Ronald A. Lubet connects Carcinogenesis with Cancer research in his research. Ronald A. Lubet connects Biochemistry with Pharmacology in his research. He performs multidisciplinary study on Pharmacology and Biochemistry in his works. His research brings together the fields of Adenocarcinoma and Genetics.

Ronald A. Lubet most often published in these fields:

Internal medicine (93.75%)
Cancer (75.00%)
Cancer research (56.25%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Chemopreventive Effect of Curcumin, a Naturally Occurring Anti-Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer

Toshihiko Kawamori;Ronald Lubet;Vernon E. Steele;Gary J. Kelloff.
Cancer Research (1999)

851 Citations

Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat.

Ronald A. Lubet;Richard T. Mayer;John W. Cameron;Raymond W. Nims.
Archives of Biochemistry and Biophysics (1985)

790 Citations

The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.

Russell F. Jacoby;Karen Seibert;Carolyn E. Cole;Gary Kelloff.
Cancer Research (2000)

704 Citations

Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis

Bandaru S. Reddy;Yoshinobu Hirose;Ronald Lubet;Vernon Steele.
Cancer Research (2000)

634 Citations

Progress in Cancer chemoprevention : Development of diet-derived chemopreventive agents

Gary J. Kelloff;James A. Crowell;Vernon E. Steele;Ronald A. Lubet.
Journal of Nutrition (2000)

595 Citations

Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.

Susan M. Fischer;Herng-Hsang Lo;Gary B. Gordon;Karen Seibert.
Molecular Carcinogenesis (1999)

507 Citations

Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam

Russell F. Jacoby;David J. Marshall;Michael A. Newton;Kristian Novakovic.
Cancer Research (1996)

404 Citations

Lipoxygenase inhibitors as potential cancer chemopreventives.

Vernon E. Steele;Cathy A. Holmes;Ernest T. Hawk;Levy Kopelovich.
Cancer Epidemiology, Biomarkers & Prevention (1999)

379 Citations

Celecoxib Inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced Urinary Bladder Cancers in Male B6D2F1 Mice and Female Fischer-344 Rats

Clinton J. Grubbs;Ronald A. Lubet;Alane T. Koki;Kathleen M. Leahy.
Cancer Research (2000)

378 Citations

Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats.

Michael A. Pereira;Clinton J. Grubbs;Leta H. Barnes;Hong Li.
Carcinogenesis (1996)

355 Citations

If you think any of the details on this page are incorrect, let us know.